Caremark settles with US FTC to resolve claims over rebating practices
MLex Summary: Caremark reached a settlement with the US Federal Trade Commission to resolve claims that the company artificially inflated the list price of insulin drugs by using anticompetitive and unfair...To view the full article, register now.
Already a subscriber? Click here to view full article